ReviewDrugs & aging2018
IgG4-Related Disease: Beyond Glucocorticoids.
Review in Drugs & aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Clinical characteristics and multimodal imaging insights of coronary involvement in immunoglobulin G4-related disease.Frontiers in immunology · 2025Pooled it
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- Extrafollicular Tph2-like cell dominant tissue pathotype is associated with relapse in IgG4-related disease.Rheumatology (Oxford, England) · 2026Article
- Case Report: A case of primary IgG4-related skin disease presenting initially with skin papules and abscesses.Frontiers in immunology · 2026Article
- Autoimmune Pancreatitis: A Review.Journal of clinical medicine · 2025Review
- Treatment Strategies for Chronic Pancreatitis (CP).Pharmaceuticals (Basel, Switzerland) · 2025Review
- Pharmacological Management of IgG4-Related Disease: From Traditional to Mechanism-Based Targeted Therapies.Drugs & aging · 2025Review
- Immune cell crosstalk between ANCA-associated vasculitis and IgG4-related disease: an unresolved pathogenic link.Frontiers in immunology · 2025Review
- Comparative Analysis of Classification Criteria in IgG4-Related Disease and Evaluating Diagnostic Accuracy from a Retrospective Cohort in Clinical Practice.Diagnostics (Basel, Switzerland) · 2024Article
- Successful remission induction of IgG4-related ophthalmic disease by obinutuzumab therapy: a retrospective study of 8 patients.Eye (London, England) · 2024Article
- Autoimmune pancreatitis: Cornerstones and future perspectives.World journal of gastroenterology · 2024Review
- Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study.Clinical rheumatology · 2023Article
- Challenges for clinicians treating autoimmune pancreatitis: Current perspectives.World journal of clinical cases · 2023Review
- Budesonide with Low-Dose 6-Mercaptopurine as a Possible New Treatment for IgG4-Related Sclerosing Cholangitis and Systemic IgG4-Related Disease: A Case Report.The American journal of case reports · 2022Article
- IgG4-Related Chronic Sinonasal Pseudotumor with Refractory Nasal Bleeding: A Case Report.Medicina (Kaunas, Lithuania) · 2022Article
- Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease-a retrospective investigation of 845 patients and its clinical relevance.Clinical rheumatology · 2022Article
- A rare case of IgG4-related disease masquerading as periurethral malignancy and review of the literature.Frontiers in immunology · 2022Review
- Left Ventricular Dysfunction Caused by IgG4-related Small Intramural Coronary Periarteritis.Internal medicine (Tokyo, Japan) · 2022Article
- IgG4-related disease in patients with idiopathic orbital inflammation.BMC ophthalmology · 2021Article
- IgG4-related hypophysitis.Endocrine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgG4-related disease is a heterogeneous immune-mediated fibroinflammatory condition that can affect every single organ. This disease is more prevalent in the elderly (the mean age of patients is above 60 years) and the prevalence rate is estimated to be over 4.6 per 100,000 population. Before making a diagnosis, the exclusion of malignancies, lymphoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, multicentric Castleman disease, and other mimickers is crucial for appropriate treatment. Broad management guidelines have been published emphasizing the need for prompt treatment and the use of glucocorticoids as first-line drug therapy for induction of remission. However, the toxic effects of glucocorticoids are problematic because IgG4-related disease is more prevalent in patients above 60 years of age, a population with frequent comorbid conditions and polypharmacy. Immunosuppressants (cyclophosphamide, methotrexate, leflunomide, and tacrolimus) and targeted immunomodulators (rituximab, XmAb5871, and abatacept) are appealing to overcome potential toxic effects of glucocorticoids and as emerging glucocorticoid-sparing and/or maintenance treatments. In this review, we provide an overview of our understanding of the pathophysiology of the disease (T follicular helper cells, CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.